Back to Search
Start Over
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Sep 11; Vol. 14, pp. 1234237. Date of Electronic Publication: 2023 Sep 11 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Background: Conventional glucocorticoids (C-GC) replacement regimens have a detrimental effect on skeletal health in patients with adrenal insufficiency (AI), ultimately leading to an increased fracture risk. The novel dual-release hydrocortisone (DR-HC) formulations are characterized by a more favourable safety profile on various clinical endpoints. Data comparing the impact of C-GC and DR-HC on bone, however, are scarce.<br />Methods: Twenty-seven patients with autoimmune primary AI (PAI; 13 treated with C-GC and 14 treated with DR-HC) were evaluated to compare bone-related parameters between the two treatment groups.<br />Results: No significant differences between the two treatments groups were observed with respect to bone turnover markers. Patients treated with C-GC showed a lower bone mineral density (BMD) at lumbar spine (LS; 0.791 ± 0.195 vs. 0.942 ± 0.124 g/cm <superscript>2</superscript> , p=0.025) and at femoral neck (FN; 0.633 ± 0.114 vs. 0.716 ± 0.088 g/cm <superscript>2</superscript> , p=0.045). Moreover, they were characterized by a lower trabecular bone score (TBS; 1.236 ± 0.035 vs. 1.383 ± 0.030, p=0.004) and by a higher mean number of vertebral fractures per patient (0.75 vs. 0 fractures, p=0.002). TBS was the best predictor of fracture risk, with a pseudo-R <superscript>2</superscript> of 0.593; moreover, at mediation analysis, it was able to fully explain the observed detrimental effect of C-GC, compared to DR-HC, on fracture risk.<br />Conclusions: These results suggest that DR-HC is associated with less bone-related complications compared to C-GC in patients with PAI. Moreover, TBS seems to play a pivotal role in the mediation of the relationship between glucocorticoid treatment regimens and fracture risk.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Bioletto, Barale, Parasiliti-Caprino, Giannelli, Campioni, Cappiello, Di Carlo, Ghigo, Procopio and Giordano.)
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 37766685
- Full Text :
- https://doi.org/10.3389/fendo.2023.1234237